NIDDK is looking to support COVID-19 research, while Emergent Ventures unveils a fast-funding program.
There is an urgent need for research on COVID-19. If you have research ideas, we want to make you aware of the following funding opportunities.
For current NIDDK grantees
NIDDK is encouraging the submission of applications for Competitive Revisions to active grants to address COVID-19 research. You must be currently funded to apply.
- NIDDK Urgent Competitive Revision Supplements on COVID-19 within the Mission of NIDDK — NIDDK is interested in projects focusing on the direct action of the virus on kidney, GI tract function and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal and endocrine/metabolic sequelae of viral infection.
- NIDDK Urgent Competitive Revision Supplements on COVID-19 Related to HIV Comorbidities, Coinfections and Complications — NIDDK is interested in studies to elucidate if COVID-19 might provoke or exacerbate noncommunicable gastrointestinal, liver, kidney/urological and metabolic/endocrine diseases in people with HIV or worsen the consequences of viral hepatitis coinfection. There is also interest in studies exploring whether people with HIV-associated comorbidities, coinfections and complications have different COVID-19 outcomes.
Open to all
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, Emergent Ventures invites you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If they approve the grant, you’ll receive payment as quickly as your university can receive it. Emergent Ventures is affiliated with the Mercatus Center at George Mason University.